Holen Sie sich die Stockscreener-App
9.44
3.51%
0.32
Schlusskurs vom Vortag:
$9.12
Offen:
$9.1
24-Stunden-Volumen:
14,005
Relative Volume:
0.02
Marktkapitalisierung:
$59.62M
Einnahmen:
$71,000
Nettoeinkommen (Verlust:
$-2.47M
KGV:
-0.2868
EPS:
-32.9143
Netto-Cashflow:
$-5.24M
1W Leistung:
+1.72%
1M Leistung:
-4.26%
6M Leistung:
-38.13%
1J Leistung:
-55.68%
1-Tages-Spanne:
$9.10
$9.47
1-Wochen-Bereich:
$9.10
$9.6683
52-Wochen-Spanne:
$6.00
$28.44
Pavmed Inc Stock (PAVM) Company Profile
Firmenname
Pavmed Inc
Sektor
Branche
Telefon
(212) 949-4319
Adresse
360 MADISON AVENUE, NEW YORK, NY
Compare PAVM vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PAVM
Pavmed Inc
|
9.44 | 57.60M | 71,000 | -2.47M | -5.24M | -32.91 |
ABT
Abbott Laboratories
|
96.00 | 168.22B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
338.34 | 131.49B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
85.00 | 110.66B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
60.99 | 95.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.44 | 46.69B | 6.07B | 1.06B | 1.34B | 1.8063 |
Pavmed Inc Stock (PAVM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-05 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2018-06-28 | Eingeleitet | Maxim Group | Buy |
Pavmed Inc Aktie (PAVM) Neueste Nachrichten
Lucid Diagnostics (NASDAQ: LUCD) seeks 100M-share authorization increase - Stock Titan
PAVmed (PAVM) price target increased by 2,900.00% to 321.30 - MSN
PAVmed Inc. Series Z Warrant (PAVMZ) - Minichart
Victoria Tou Ho Lee Net Worth (2026) - GuruFocus
Dana Carrera, Tasso Partners disclose 15.3% stake in PAVmed (NASDAQ: PAVM) - Stock Titan
70,000-share PAVmed (PAVM) restricted stock grant to CMO - Stock Titan
[Form 3] PAVmed Inc. Initial Statement of Beneficial Ownership - Stock Titan
Scopia Holdings/Member Matthew Sirovich reports 9.99% in PAVmed (PAVM) - Stock Titan
Risk Report: Is PAVmed Inc forming higher highs and higher lows2026 Technicals & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025 - Quantisnow
PAVmed (PAVM) price target decreased by 16.51% to 268.26 - MSN
Treasury Yields: Is PAVmed Inc a potential multi bagger2026 Summary & High Return Trade Guides - baoquankhu1.vn
Aug Reactions: Can PAVmed Inc expand into new markets2026 Snapshot & Weekly Stock Performance Updates - baoquankhu1.vn
Lishan Aklog Discloses Investment at PAVmed Inc. with 5.1% Stake - TradingView
PAVmed (PAVM) CEO Aklog reports 5.1% stake and 350,000 restricted shares - Stock Titan
Lucid Diagnostics to Participate in Fireside Chat at the 25th An - GuruFocus
Lucid Diagnostics CEO to Participate in Healthcare Conference - Intellectia AI
Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference - Barchart.com
Lucid CEO to speak at Needham healthcare conference on April 16 - Stock Titan
Entry Recap: Can PAVmed Inc be recession proofQuarterly Growth Report & Fast Moving Trade Plans - baoquankhu1.vn
How The PAVmed (PAVM) Narrative Is Shifting After The Latest Analyst Reassessment - Yahoo Finance
Nagelberg disclosures show 8.6% ownership in PAVmed (NASDAQ: PAVM) - Stock Titan
Aug PostEarnings: Can PAVmed Inc sustain its profitability2026 Growth vs Value & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
PAVmed (NASDAQ: PAVM) Scott Dols reports 5.4% stake, 346,155 shares - Stock Titan
PAVM Appoints Joseph Virgilio to Oversee Revamp of Medical Device Portfolio - Bitget
PAVM Assigns Joseph Virgilio to Lead Medical Device Portfolio Relaunch - Yahoo Finance
Tasso Partners, LLC (PAVM) reports large PAVmed stake and warrant position - Stock Titan
EV Market: Will PAVmed Inc benefit from rate cuts2026 Price Targets & Weekly Return Optimization Alerts - baoquankhu1.vn
Q3 2025 PAVmed Inc Earnings Call Transcript - GuruFocus
Big Money Moves: Whats next for PAVmed Inc stockBuy Signal & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
PAVM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
PAVmed (PAVM) CEO Lishan Aklog awarded 350,000 restricted shares vesting 2029 - Stock Titan
Craig Kallman (PAVM) holds 384,616 shares, a 6.0% stake in PAVmed - Stock Titan
PAVmed (PAVM) CFO awarded 180,000 restricted shares vesting 2029 - Stock Titan
Director at PAVmed (PAVM) receives 13,930 restricted stock shares - Stock Titan
PAVmed (PAVM) director Timothy Baxter receives 13,930 restricted shares vesting in 2029 - Stock Titan
Restricted stock grant boosts PAVmed (PAVM) director’s holdings - Stock Titan
PAVmed (PAVM) director gets 13,930-share restricted stock grant - Stock Titan
Restricted stock award boosts PAVmed (NASDAQ: PAVM) director stake - Stock Titan
Tasso Partners and Dana Carrera disclose 14.3% stake in PAVmed (PAVM) - Stock Titan
PAVmed (PAVM) general counsel receives 110,000-share restricted award - Stock Titan
PAVmed (PAVM) COO receives 110,000-share restricted stock grant vesting 2029 - Stock Titan
Lucid Diagnostics Inc. (LUCD) stock price, news, quote and history - Yahoo Finance UK
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio - Bitget
PAVmed appoints Joseph Virgilio as medical device chief By Investing.com - Investing.com Australia
PAVmed raises $45 million, restructures capital to eliminate convertible debt - Investing.com
PAVmed Appoints New Executive to Drive Medical Device Development - Intellectia AI
PAVmed: Octeris, Inc. Subsidiary Formed to Advance Endoscopic Esophageal Imaging Tech Recently Licensed From Duke University >PAVM - Moomoo
PAVmed appoints Joseph Virgilio as medical device chief - Investing.com
PAVmed Inc. (NASDAQ:PAVM) Q4 2025 Earnings Call Transcript - Insider Monkey
PAVmed raises $45 million, restructures capital to eliminate convertible debt By Investing.com - Investing.com India
Finanzdaten der Pavmed Inc-Aktie (PAVM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):